MIP/2003/FIN/CDS ENGLISH ONLY WORLD HEALTH ORGANIZATION COMMUNICABLE DISEASES INTERIM FINANCIAL STATUS REPORT FOR THE YEAR 2002 FINANCIAL PERIOD 2002 2003 COVERING THE PERIOD 1 JANUARY 2002 31 DECEMBER 2002 Incorporating the former Communicable Diseases Cluster excludes HIV/AIDS. From 2004, workplans and s will reflect the Communicable Diseases (CDS) Cluster and the HIV/AIDS, Tuberculosis and Malaria (HTM) Cluster OCTOBER 2003
Contents Financial tables Table 1 CDS operating for 2002 2003 3 Table 2 Summary financial status for the year 2002 4 Table 3 and Fig. 1 CDS operating compared with funds available and expenditures, all sources of funds by Area of Work 5 Table 4 Contributions and other income received in 2002 6 Notes 8 This report captures all income contributed by donors to the Communicable Diseases (CDS) at Headquarters in Geneva. Expenditure (which may be on activities in Geneva or in regions and countries) excludes funds transferred by CDS to regional offices. 2.
Table 1: CDS operating for 2002-2003 as at 31 December 2002 1. Regular WHO Programme Budget (PB): regular Regular by Area of Work and other components Other sources operating Communicable disease surveillance 8,928 8,438 Communicable disease prevention, eradication and control 12,484 6,367 Research and product development for communicable diseases 3,772 2,811 Malaria 4,526 6,291 Tuberculosis 1,131 2,665 Executive Director/ management support unit 4,269 Regular 2002-2003 30,841 30,841 (Reference WHO PPB/02-03) Net ary adjustments (Note 1) (1824) Operational regular 2002-2003 29 017 (Reference WHO Unaudited Interim Financial Report for 2002, Table 3) 2. Other sources and adjustments to form operating Other sources (Note 2) 339 924 Total other sources operating 2002-2003 339 924 3. Operating broken down by Area of Work, EXD (Reference Table 3) Total Regular Other sources Communicable disease surveillance 55 798 8 593 47 205 Communicable disease prevention, eradication and control 50 652 5 805 44 847 Research and product development for communicable diseases 95 217 2 562 92 655 Malaria 60 641 5 735 54 906 Tuberculosis 95 343 2 430 92 913 Executive Director/management support unit 11 290 3 892 7 398 Total operating 2002-2003 (Note 3) 368 941 29 017 339 924 3.
Table 2: CDS summary financial status for the year 2002 as at 31 December 2002 Breakdown by source of funds Regular Other sources Total Operating Opening balance 1 January 2002 ( Note 4) a 0 90 187 90 187 Income b 29 017 118 735 147 752 (Reference Table 4) Total funds a + b=c 29 017 208 922 237 939 368 941 Transfers To regions and clusters (Note 5) 0 (67 819) (67 819) Total transfers d 0 (67 819) (67 819) Funds available at headquarters (operating income) c - d=e 29 017 141 103 170 120 ( Note 6) Expenditures f 13 663 92 172 105 835 (Reference WHO Unaudited Interim Financial Report for 2002, Table 3) Balance available at headquarters at 31 December 2002 e - f=g 15 354 48 931 64 285 Interest accrued in 2002 for use in 2004-2005 h 0 5 832 5 832 Balance of funds transferred by headquarters to regions or clusters at 31 December 2002 j 0 31 376 31 376 Closing balance 31 December 2002 (Note 7) k=g + h + j 15 354 86 139 101 493 4.
Table 3: CDS operating compared with funds available and expenditures, all sources of funds by Area of Work as at 31 December 2002 Implementation rates Income received in Cluster 2002 net of transfers operating to regional offices and clusters Funds available Expenditures Expenditure/ Expenditure/ funds available Communicable disease surveillance (CSR) 55 798 24 322 38 974 22 881 41% 59% Communicable disease prevention, eradication and control (CPE) 50 652 9 846 28 554 13 832 27% 48% Research and product development for communicable diseases (TDR) 95 217 29 558 36 751 23 542 25% 64% Malaria (MAL) 60 641 (8 848) 20 624 13 537 22% 66% Tuberculosis (STB) 95 343 17 731 34 034 27 423 29% 81% Executive Director/management support unit (EXD/MSU) 11 290 7 324 11 183 4 620 41% 41% Total 368 941 79 933 170 120 105 835 29% 62% Reference Table 1 Table 2 Table 2 Figure 1: CDS operating, funds available and expenditures 120,000 100,000 80,000 operating funds available expenditures 60,000 40,000 20,000 0 CSR CPE TDR RBM STB EXD/MSU 5.
Table 4: CDS Contributions and other income received in 2002 Contributions to the Voluntary Fund for Health Promotion & TDR Trust Fund as at 31 December 2002 2002 Unspecified Specified Total Firm pledges Donor countries Australia 867,193 490,537 1,357,730 0 Belgium 368,695 912,970 1,281,665 0 Canada 0 10,958,221 10,958,221 0 Cyprus 0 20,000 20,000 0 Denmark 0 1,984,127 1,984,127 0 France 0 2,431,344 2,431,344 25,543 Germany 1,253,893 1,097,405 2,351,298 464,326 Greece 0 20,000 20,000 India 0 25,000 25,000 0 Ireland 83,483 751,351 834,834 728,922 Italy 795,075 3,182,702 3,977,777 0 Japan 770,000 2,125,000 2,895,000 0 Kuwait 0 20,000 20,000 0 Lebanon 0 61,642 61,642 0 Luxembourg 758,123 918,968 1,677,091 0 Malaysia 0 25,000 25,000 0 Netherlands 3,898,983 4,339,180 8,238,163 6,537,217 New Zealand 0 42,930 42,930 0 Norway 2,268,292 3,433,838 5,702,130 Republic of Korea 10,000 203,750 213,750 122,250 Spain 16,598 75,647 92,245 0 Sweden 0 2,510,186 2,510,186 0 Switzerland 33,557 635,141 668,698 184,892 Syria 0 60,000 60,000 0 Thailand 0 35,768 35,768 0 Turkey 0 25,000 25,000 0 United Kingdom 2,081,250 21,942,433 24,023,683 160,256 United States of America 32,770 14,129,930 14,162,700 19,525,701 Miscellaneous (below US $20,000) 0 46,571 46,571 0 sub-total, donor countries 13,237,912 72,504,641 85,742,553 27,749,107 % of category 15% 85% 100% UN organizations and agencies Joint United Nations Programme on HIV/AIDS 0 448,630 448,630 0 United Nations Children's Fund 0 150,000 150,000 0 United Nations Development Programme 24,977 0 24,977 0 United Nations Fund for International Partnerships 0 0 0 1,503,500 World Bank 0 3,295,300 3,295,300 0 World Bank (Bill & Melinda Gates Foundation) 0 3,600,000 3,600,000 0 sub-total, UN organizations and agencies 24,977 7,493,930 7,518,907 1,503,500 % of category 0.33% 99.66% 100% Other contributors African Programme For Onchocerciasis Control, Burkina Faso 0 1,620,000 1,620,000 0 Arab Gulf Programme for UN Development Organizations 0 0 0 60,000 Aventis Environmental Science SA, France 12,000 0 12,000 0 Aventis Pasteur SA, France 5,000 0 5,000 0 Aventis Pharma, Deutschland GMBH, Germany 0 2,470,127 2,470,127 0 BASF Corp., USA 4,500 0 4,500 0 Bayer AG., Germany 17,979 0 17,979 0 Bill & Melinda Gates Foundation 0 4,425,000 4,425,000 4,500,000 Bristol Meyers Squibb, USA 0 400,000 400,000 0 CIBC World Markets Corporation, USA 2,700 2,700 0 City of Lyon, France 0 274,617 274,617 585,926 6.
Commission of the European Communities 0 137,660 137,660 0 Crompton Europe B.V., Netherlands 10,000 0 10,000 0 EURO Health Group A/S, Denmark 0 39,723 39,723 0 FMC Corporation, USA 4,500 0 4,500 0 Fondation Follereau, France 31,697 0 31,697 0 Fondation Mérieux, France 0 1,441,446 1,441,446 0 Fundacion Anesvad, Spain 105,000 0 105,000 0 Glaxo SmithKline, UK 51,000 110,000 161,000 0 Global Forum for Health Research, Switzerland 0 250,000 250,000 0 Health Research Inc., USA 16,200 0 16,200 0 Infectious Disease Research Institute, USA 0 200,000 200,000 0 International Development Research Centre, Canada 0 16,890 16,890 0 International Federation of Pharmaceutical Manufacturers Associations 0 50,000 50,000 0 Liverpool School of Tropical Medicine, UK 14,822 0 14,822 0 London School of Hygiene & Tropical Medicine, UK 0 773,438 773,438 0 Makhteshim Chemical Works Ltd., Israel 14,975 0 14,975 0 Medicines for Malaria Venture, Switzerland 0 1,138,363 1,138,363 0 Merck & Co Inc., USA 25,000 0 25,000 0 New York Community Trust, USA 0 50,000 50,000 0 Nippon Foundation, Japan 0 600,000 600,000 0 Novartis Foundation, Switzerland 25,000 872,353 897,353 0 Nuclear Threat Initiative, USA 0 500,000 500,000 0 Onchocerciasis Control Programme, Burkina Faso 0 225,000 225,000 0 Open Society Institute, USA 0 219,500 219,500 0 Procter & Gamble AG, Switzerland 0 46,940 46,940 0 Research Institute of Tuberculosis, Japan 14,040 0 14,040 0 Rockefeller Foundation 13,300 962,040 975,340 0 Sasakawa Health Trust Fund 0 4,865,000 4,865,000 0 Sumito Chemical Company Ltd, Japan 75,800 0 75,800 0 The Task Force for Child Survival & Development 9,183 0 9,183 0 TIFA (C.I.) Limited, USA 15,000 0 15,000 0 University Hospital of North Norway 0 25,425 25,425 0 University of Harvard, USA 0 438,124 438,124 0 Valent Biosciences Corp. 42,000 0 42,000 0 Vestergaard Frandsen A/S, Denmark 42,000 0 42,000 0 Wellcome Trust, UK 0 29,000 29,000 0 Zenryokyo Fund, Japan 22,375 0 22,375 0 Miscellaneous 106,757 262,785 369,542 0 Administrative support funds(as) 0 2,944,011 2,944,011 0 Sub-total, other contributions 680,828 25,387,442 26,068,270 5,145,926 % of category 3% 97% 100% Total income prior to adjustment 13,943,717 105,386,013 119,329,730 34,398,533 % of category 12% 88% 100% Adjustments, refunds and rebates 0-595,162-595,162 0 Total Other Sources 13,943,717 104,790,851 118,734,568 34,398,533 % of category 12% 88% 100% WHO Regular 0 29,017,668 29,017,668 0 Sub.total WHO contribution 0 29,017,668 29,017,668 0 % of category 0% 100% 100% Total income 13,943,717 133,808,519 147,752,236 34,398,533 % of category 9% 91% 100% 7.
Notes 1. Net ary adjustments include reductions in the regular made centrally to reflect corporate efficiency savings and changes in exchange rates. 2. The other sources operating reflects the cost of planned activities within the areas of work in CDS. 3. These figures correspond to the areas of work in CDS in the 2002-2003 programme. 4. This represents the opening balance at Headquarters plus unexpended balance at Regional Offices as of 1 January 2002. 5. Transfers to regions amounted to US$ 67.8 million of which more than 50% were transferred to the Regional Office of Africa. 6. Funds available at Headquarters for programme implementation after transfers to the regions. 7. This is the sum total of balance available on 31 December 2002 at Headquarters and in the regions including accrued interest. 8.